These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. Nemeroff CB J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):10S-17S. PubMed ID: 8106649 [TBL] [Abstract][Full Text] [Related]
85. Paroxetine: an overview of dosage, tolerability, and safety. Jenner PN Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():69-80. PubMed ID: 1431015 [TBL] [Abstract][Full Text] [Related]
86. Clinical overview of serotonin reuptake inhibitors. Rickels K; Schweizer E J Clin Psychiatry; 1990 Dec; 51 Suppl B():9-12. PubMed ID: 2147922 [TBL] [Abstract][Full Text] [Related]
87. A review of the clinical safety and tolerability of nomifensine. Stonier PD J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):89-95. PubMed ID: 6370984 [TBL] [Abstract][Full Text] [Related]
89. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. Tulloch IF; Johnson AM J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829 [TBL] [Abstract][Full Text] [Related]
90. Recent pharmacologic advances in antidepressant therapy for the elderly. Preskorn SH Am J Med; 1993 May; 94(5A):2S-12S. PubMed ID: 8503477 [TBL] [Abstract][Full Text] [Related]
92. [New antidepressant drugs. What side effects and interactions are to be expected?]. Degner D; Grohmann R; Bleich S; Rüther E MMW Fortschr Med; 2000 Dec; 142(49-50):35-8, 40. PubMed ID: 11190936 [TBL] [Abstract][Full Text] [Related]
93. The safety profile of nefazodone. Robinson DS; Roberts DL; Smith JM; Stringfellow JC; Kaplita SB; Seminara JA; Marcus RN J Clin Psychiatry; 1996; 57 Suppl 2():31-8. PubMed ID: 8626361 [TBL] [Abstract][Full Text] [Related]
95. Paroxetine: a pharmacological review. Johnson AM Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():15-24. PubMed ID: 1331230 [TBL] [Abstract][Full Text] [Related]
96. Expanding psychopharmacologic treatment options for the depressed medical patient. Stoudemire A Psychosomatics; 1995; 36(2):S19-26. PubMed ID: 7724709 [TBL] [Abstract][Full Text] [Related]
97. The medical consequences of the selection of an antidepressant. Nierenberg AA J Clin Psychiatry; 1992 Sep; 53 Suppl():19-24. PubMed ID: 1522076 [TBL] [Abstract][Full Text] [Related]
98. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Warrington SJ; Lewis Y Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 4():59-64. PubMed ID: 1431013 [TBL] [Abstract][Full Text] [Related]
99. The cardiovascular effects of antidepressants. Warrington SJ; Padgham C; Lader M Psychol Med Monogr Suppl; 1989; 16():i-iii, 1-40. PubMed ID: 2690161 [TBL] [Abstract][Full Text] [Related]
100. [Driving fitness in therapy with antidepressive drugs]. Soyka M; Dittert S; Gartenmeier A; Schäfer M Versicherungsmedizin; 1998 Apr; 50(2):59-66. PubMed ID: 9587241 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]